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Abstract
We investigated the occurrence of bleeding complications in patients who underwent skin tumor surgery and
compared it between Aspirin users and a placebo control group. In this double blind randomized controlled trial,
32 patients who continued taking aspirin (intervention group) and 38 patients who stopped taking Aspirin (placebo
group) before surgery were compared in terms of intraoprative and postoperative bleeding problems, hematoma
and local signs of coagulopathy. There was no statistically significant difference in intraoprative bleeding between
the study groups (P = 0.107). We concluded that continuation of Aspirin therapy had no significant effect on
bleeding complications in patients who underwent skin tumor surgery.
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Discontinuation of anticoagulant or anti platelet agents
before skin surgery is still a challenge due to the lack of
proper recommendations in the current guidelines [1].
For the decision making, the surgeon should consider
several patient-related factors, such as indication of the
treatment, patient’s condition and the underlying dis-
ease, in order to decide about the continuation or inter-
ruption of the drug [2, 3]. Skin surgeries are considered
as one of the safest and simplest surgeries. However,
rapid increase in the use and new indications of anti-
coagulant drugs, particularly aspirin, requires specific at-
tention toward their use in skin surgeries [4, 5].
However, the evidence regarding the continuation or
discontinuation of Aspirin before skin surgery is incon-
sistent. In the present study, we aimed to monitor the
bleeding complications in patients who underwent skin
tumor surgery and compared it between Aspirin users
and a placebo control group.
In this double-blind randomized controlled trial, we en-
rolled patients with non-bleeding skin tumors who were
under treatment with aspirin due to any indication. The
inclusion criteria were use of Aspirin for at least 3 months
before surgery with a daily dose of 80 mg, age between 40
and 75 years, giving an informed consent for taking part
in the study, and international normalized ratio (INR) of
1–1.5. Our exclusion criteria included as follows; Having
dementia, movement disorder, simultaneous participation
in another trial, patients with life-threatening cardiovascu-
lar diseases (i.e. New York Heart Association class III or
more, history of previous myocardial infarction, severe
heart valve disease), bleeding disorders, use of antiplatelets
other than Aspirin or anticoagulants and positive history
of gastrointestinal bleeding. Moreover, patients who did
not follow the prescription rules, those who had a disease
that required Aspirin discontinuation or Aspirin intoler-
ance were also excluded. In order to make sure about the* Correspondence: H_abianeh@yahoo.com
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drug compliance of the patients, they were asked to bring
the blister pack of the consumed tablets.
Using block randomization, patients were randomized
into intervention and control groups, matched for age and
sex. Both groups were asked to discontinue their Aspirin
7 days before the surgery and they received packed drugs
of the trial including Aspirin (80 mg) for the intervention
group and placebo for the control group.
Before operation, demographic and baseline clinical char-
acteristics were collected from the patients. The clinical
data included the presence of bleeding risk factors, type of
skin tumor, number and size of the tumor(s), location of
the lesion, drug history and blood test. For every patient,
standard resection for the tumor was performed regarding
its size and other clinical characteristics. Type of operation
and data regarding anesthesia, cautery, need for osteotomy
and other surgical characteristics were recorded for the pa-
tient. We measured the bleeding by weighing the dressing
gases during and after operation up to 24 h. The nurse who
was in charge of weighing the gases was blinded to the
study protocol. Primary endpoint of the study was the
amount of bleeding within and early after surgery. Second-
ary endpoints were need for early changing of the dressing,
development of hematoma or local anticoagulation disor-
ders such as petechia or ecchymosis.
Categorical variables were analyzed by the chi-square test.
Continuous variables are presented as means ± standard
deviation, or as median and interquartile ranges, as appro-
priate. Differences between groups in normally and non-
normal continuous variables were assessed using the
unpaired Student’s t test and the Mann–Whitney U test,







Age, year 65.8 ± 2.3 64.1 ± 1.7 0.218
Male gender, n (%) 24 (75) 29 (76.3) 0.683
Diabetes, n (%) 13 (40.6) 5 (13.2) 0.009
Hypertension, n (%) 23 (71.9) 19 (50) 0.063
Cardiovascular diseases, n (%) 21 (65.6) 11 (28.9) 0.002
Smoking, n (%) 4 (12.5) 5 (13.2) 0.999
Opium abuse, n (%) 3 (9.4) 4 (10.5) 0.999
FBS, mg/dl 123.9 ± 58.0 121.7 ± 44.9 0.696
BUN, mg/dl 37.3 ± 8.9 33.7 ± 8.7 0.064
Creatinine, mg/dl 0.94 ± 0.24 0.95 ± 0.25 0.723
Hemoglobin, g/dl 13.7 ± 1.3 14.9 ± 4.4 0.054
Platelet, 1/mm3 208.4 ± 81.9 200.3 ± 45.1 0.925
INR 2.1 ± 4.7 1 ± 0.01 0.096
PT, sec 13.3 ± 3.2 12.9 ± 2.3 0.001
PTT, sec 28.1 ± 4.1 28.9 ± 3.2 0.114
CT, sec 327.3 ± 72.2 321.7 ± 62.9 0.669
BT, sec 152.7 ± 59.7 148.7 ± 44.6 0.791
BT Bleeding time, BUN Blood urea nitrogen, CT clotting time, FBS Fasting blood
sugar, INR International normalized ratio, PT Prothrombin time, PTT Partial
thromboplastin time
aVariables are shown as mean ± standard deviation or frequency (percentage)
where appropriate
†P < 0.05 was considered as statistically significant
Table 2 Comparison of the tumoral and operative







Face 10 (29.4) 13 (30.9)
Nose 6 (17.6) 4 (9.5)
Ear 4 (11.7) 5 (11.9)
Neck 0 (0) 1 92.3)
Scalp 9 (26.4) 14 (33.3)
Other 5 (14.7) 5 (11.9)
Type 0.675
Basal cell carcinoma 24 (75) 32 (84.2)
Squamous cell carcinoma 5 (15.6) 5 (13.2)
Melanoma 1 (3.1) 0 (0)
Not reported 2 (6.2) 1 (2.6)
Size of lesion 0.17
< 3 cm 15 (46.9) 14 (35)
3–6 cm 15 (46.9) 24 (60)
> 6 cm 1 (3.1) 2 (5)
Not reported 1 (3.1) 0 (0)
Number of lesions 0.478
1 lesion 22 (68.8) 29 (76.3)
2 lesions 3 (9.4) 6 (15.8)
3 lesions 2 (6.2) 1 (2.6)
4 lesions and more 3 (9.4) 1 (2.6)
Not reported 2 (6.2) 1 (2.6)
Type of surgery 0.72
Flap 24 (70.6) 28 (68.3)
Graft 9 (56.4) 13 (31.7)
Other 1 (2.9) 0 (0)
Type of anesthesia 0.999
Sedative 31 (96.9) 38 (100)
Not reported 1 (3.1) 0 (0)
Cautery 0.999
Monopolar 31 (96.9) 37 (97.4)
Bipolar 1 (3.1) 1 (2.6)
Need for osteotomy 0 (0) 1 (2.6)
Volume of bleeding, ml 30 [20, 80] 30 [17, 40] 0.107
aVariables are shown as frequency (percentage) or median [interquartile range]
where appropriate
†P < 0.05 was considered as statistically significant
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respectively. All probability values were two-tailed and a P-
value < 0.05 was considered significant. Data were analyzed
with Statistical Package for the Social Sciences (SPSS) for
Windows, version 15.0 (SPSS Inc., Chicago, Ilinois, United
States of America).
In the present study, 38 patients were randomized to the
intervention group and 38 patients were included in the
control group. However, after randomization it was revealed
that three patients had used antiplatelet or anticoagulant
drugs and three other patients refused to continue the study;
so, they were excluded from the final analysis (n = 32 for the
intervention group). The frequency of diabetes and cardio-
vascular disease was significantly higher in the intervention
group (P= 0.009 and P= 0.002, respectively). Details of the
demographic and baseline clinical characteristics of the
study groups are shown in Table 1.
Based on the pathology report, characteristics of the
tumors and operation were comparable between the two
groups as shown in Table 2.
Bleeding in all participants was restricted to the oper-
ation time and none of the participants had postoperative
bleeding. Median volume of bleeding was 30 gram in both
groups (P = 0.107) (Table 2). None of the patients required
early change of wound dressing and we observed no case
of hematoma or local coagulation disorder.
We found no significant difference between patients who
used Aspirin perioperatively and those who discontinued it
beforehand. This finding is in line with similar previous
studies [6–8], while the strength of our study is its random-
ized controlled trial design and its uniform population that
consisted of skin cancer patients. We also observed no
complication within the study period.
Based on our findings, perioperative Aspirin therapy had
no significant effect on bleeding complications in patients
who underwent skin tumor surgery. Currently, surgical
bleedings can be controlled easily by electrocauterization
and are not potentially life-threatening. It seems that der-
masurgeons should be more informed about the safety of
Aspirin use in skin surgeries based on the current body of
knowledge. Larger studies can also contribute to the
elucidation of the use of multiple antiplatelet and anti-
coagulant agents during skin surgeries.
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